EPSTI1 as an immune biomarker predicts the prognosis of patients with stage III colon cancer

Overview of attention for article published in Frontiers in immunology, October 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 50,094 followers.

EPSTI1 as an immune biomarker predicts the prognosis of patients with stage III colon cancer: Objective The poor prognosis and heterogeneity of stage III colon cancer (CC) suggest the need for more prognostic biomarkers. The… #immunology https://t.co/gG3w0

21 Oct 2022

Reply Repost Favourite

New Research: EPSTI1 as an immune biomarker predicts the prognosis of patients with stage III colon cancer: Objective The poor prognosis and heterogeneity of stage III colon cancer (CC) suggest the need for more prognostic biomarkers. The… https://t.co/9i

19 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.